The role of PRDM16 in cardiac development, a novel therapeutic target for heart failure
Developmental Biology
Final Report Abstract
Cardiomyopathies are a common cause of heart failure and the most frequent cause of heart transplantation. Therefore a better understanding of the underlying pathomechanism of this disease is quite important. With our study we were able to elucidate some mechanisms of PRDM16-related cardiomyopathy and additionally revealed a presumable myocyte-adipocyte differentiation axis which may identify a discrete subset of cardiomyopathy. But further studies are warranted to explore in more detail the specific pathways involving PRDM16. Furthermore, our current findings underline the importance of personalized disease models. The rescue with the MC4R antagonist might offer potential mechanistic and therapeutic insights into heart failure and in addition was filed for a patent with the title “Therapies for left ventricular noncompaction and dilated cardiomyopathy”. Nevertheless, there are still open questions which need to be answered and unfinished experiments which need to be done.
Publications
- (2014). Genetic testing in cardiovascular disease. Curr Opin Cardiol. 29(3):235-40
Arndt, A.K., MacRae C.A.
(See online at https://doi.org/10.1097/HCO.0000000000000055) - (2014). Identification of a new modulator of the intercalated disc in a zebrafish model of arrhythmogenic cardiomyopathy. Science translational medicine 6, 240ra274
Asimaki, A., Kapoor, S., Plovie, E., Arndt, A.K., Adams, E., Liu, Z., James, C.A., Judge, D.P., Calkins, H., Churko, J., et al.
(See online at https://doi.org/10.1126/scitranslmed.3008008)
